momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (4928)	7/19/2006 1:22:34 PM
From: Ian@SI	Read Replies (1) of 12215

Re HGSI being called one of the BUBBLE snow jobs. Is that still your current view? OR have they come down to a more reasonable valuation? They seem to have some nice stuff in their pipeline including a promising SLE treatment. Jun. 22 Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus Current and LT marketable assets exceed Long term debt by about $100M or almost $1 share yielding a MC less cash of about $1.1B. ARNA on the other hand has less total cash but almost the same per share; a MC under 0.5B and 9 days short interest (vs 4 for HGSI); and, a scattergun approach to trying to get an approved drug. Aren't they going to run out of money first thus being forced into disastrous financing terms?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next